Suven Life Sciences, a biopharmaceutical company has secured 2 Product Patents for their NCEs in the key markets in the world.
The company has reported a decent increase of about 26.16% in the sales to Rs. 45.65 crore for the quarter ended March 2011. The sales figure stood at Rs. 36.18 crore during the year-ago period. Net Profit for the quarter ended March 2011 zoomed to 121.44% from Rs 1.58 crore to Rs. 3.50 crore. Operating Profit margin saw a handsome growth to 11.84% from 7.09% in the quarter ended March 2011.
Suven Life Science focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: